Anginex lipoplexes for delivery of anti-angiogenic siRNA.

@article{Yousefi2014AnginexLF,
  title={Anginex lipoplexes for delivery of anti-angiogenic siRNA.},
  author={A. Yousefi and M. Bourajjaj and N. Babae and P. V. Noort and R. Schaapveld and J. R. Beijnum and A. Griffioen and G. Storm and R. Schiffelers and E. Mastrobattista},
  journal={International journal of pharmaceutics},
  year={2014},
  volume={472 1-2},
  pages={
          175-84
        }
}
Angiogenesis is one of the hallmarks of cancer which renders it an attractive target for therapy of malignancies. Tumor growth suppression can be achieved by inhibiting angiogenesis since it would deprive tumor cells of oxygen and vital nutrients. Activation of endothelial cells of tumor vasculature is the first step in angiogenesis which is mediated by various factors. One of the major triggers in this process is vascular endothelial growth factor (VEGF) which binds to VEGF receptors on… Expand
Hemocompatibility Assessment of two siRNA Nanocarrier Formulations
Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA
In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
Intracellular Delivery III

References

SHOWING 1-10 OF 60 REFERENCES
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy
The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models
Unraveling galectin-1 as a novel therapeutic target for cancer.
Tumor-targeted delivery of siRNA by self-assembled nanoparticles.
...
1
2
3
4
5
...